Amicus Therapeutics Inc (FOLD)
9.50
-0.09
(-0.94%)
USD |
NASDAQ |
Nov 21, 16:00
9.485
-0.02
(-0.16%)
After-Hours: 20:00
Amicus Therapeutics Gross Profit Margin (Quarterly): 90.62% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 90.62% |
| June 30, 2024 | 91.11% |
| March 31, 2024 | 87.71% |
| December 31, 2023 | 90.16% |
| September 30, 2023 | 90.39% |
| June 30, 2023 | 90.36% |
| March 31, 2023 | 91.95% |
| December 31, 2022 | 89.35% |
| September 30, 2022 | 83.55% |
| June 30, 2022 | 89.85% |
| March 31, 2022 | 90.37% |
| December 31, 2021 | 90.44% |
| September 30, 2021 | 85.30% |
| June 30, 2021 | 89.17% |
| March 31, 2021 | 90.15% |
| December 31, 2020 | 86.66% |
| September 30, 2020 | 87.55% |
| Date | Value |
|---|---|
| June 30, 2020 | 89.29% |
| March 31, 2020 | 89.17% |
| December 31, 2019 | 87.44% |
| September 30, 2019 | 88.53% |
| June 30, 2019 | 87.84% |
| March 31, 2019 | 88.09% |
| December 31, 2018 | 86.69% |
| September 30, 2018 | 79.07% |
| June 30, 2018 | 85.29% |
| March 31, 2018 | 84.34% |
| December 31, 2017 | 82.28% |
| September 30, 2017 | 83.54% |
| June 30, 2017 | 85.18% |
| March 31, 2017 | 81.41% |
| December 31, 2016 | 82.73% |
| September 30, 2016 | 83.83% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
83.55%
Minimum
Sep 2022
91.95%
Maximum
Mar 2023
89.03%
Average
89.60%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 44.90% |
| Alnylam Pharmaceuticals Inc | 82.85% |
| Ionis Pharmaceuticals Inc | 99.20% |
| Arbutus Biopharma Corp | -- |
| Krystal Biotech Inc | 92.03% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -71.17% |
| Return on Assets | -13.78% |
| Return on Invested Capital | -19.50% |
| Profit Margin (Quarterly) | -4.75% |
| Operating Margin (Quarterly) | 17.53% |
| Return on Net Operating Assets | -24.20% |